Genomic sequencing Evaluation of 733 HER2-amplified Principal and metastatic breast tumours discovered sizeable enrichment of mutations that activate RAS–MAPK signalling in State-of-the-art tumours dealt with with prior anti-HER2 therapies121. These mutations, such as NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. Palliative care is a Exclusive https://www.directivepublications.org/journal-of-clinical-breast-cancer/